Kentaro Ando

Kentaro Ando

Auto-generated profile, based on publicly available information

Kentaro Ando

Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
KAKentaro Ando
Kentaro Ando
THToshiyasu Hombo
Toshiyasu Hombo
AKAkihiro Kanno
Akihiro Kanno
HIHironobu Ikeda
Hironobu Ikeda
MIMasakazu Imaizumi
Masakazu Imaizumi
KYKeiji Yamamoto
Keiji Yamamoto
In safety pharmacology studies, the effects on the QT interval of electrocardiograms are routinely assessed using a telemetry system in cynomolgus monkeys. However, there is a lack of integrated databases concerning in vivo QT assays in conscious monkeys. As part of QT Interval Prolongation: Project for Database Construction (QT PRODACT), the present study examined 10 positive compounds with the potential to prolong the QT interval and 6 negative compounds considered to have no such effect on humans. The experiments were conducted at 7 facilities in accordance with a standard protocol established by QT PRODACT. The vehicle or 3 doses of each test compound were administered orally to male cynomolgus monkeys (n = 3 – 4), and telemetry signals were recorded for 24 h. None of the negative compounds prolonged the corrected QT using Bazett’s formula (QTcB) interval. On the other hand, almost all of the positive compounds prolonged the QTcB interval, but haloperidol, terfenadine, and thioridazine did not. The failure to detect the QTcB interval prolongation appeared to be attributable for the differences in metabolism between species and/or disagreement with Bazett’s formula for tachycardia. In the cynomolgus monkeys, astemizole induced Torsade de Pointes and cisapride caused tachyarrhythmia at lower plasma concentrations than those observed in humans and dogs. These results suggest that in vivo QT assays in conscious monkeys represent a useful model for assessing the risks of drug-induced QT interval prolongation. Supplementary material (Appendix): available only at http://dx.doi.org/10.1254/jphs.QT-A4

1 January 2014 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
YNYuji Nakamura
Yuji Nakamura
JMJunko Matsuo
Junko Matsuo
NMNorimasa Miyamoto
Norimasa Miyamoto
AOAtsuko Ojima
Atsuko Ojima
KAKentaro Ando
Kentaro Ando
YSYuko Sekino
Yuko Sekino
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

31 October 2014 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
HOHiroshi Ohara
Hiroshi Ohara
YNYuji Nakamura
Yuji Nakamura
YWYudai Watanabe
Yudai Watanabe
XCXin Cao
Xin Cao
YYYukiko Yamazaki
Yukiko Yamazaki
ASAtsushi Sugiyama
Atsushi Sugiyama

1 September 2017 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
HIHiroko Izumi-Nakaseko
Hiroko Izumi-Nakaseko
YKYasunari Kanda
Yasunari Kanda
YNYuji Nakamura
Yuji Nakamura
MHMihoko Hagiwara-Nagasawa
Mihoko Hagiwara-Nagasawa
TWTakeshi Wada
Takeshi Wada
ASAtsushi Sugiyama
Atsushi Sugiyama
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been used in many studies to assess proarrhythmic risks of chemical compounds. In those studies, field potential durations (FPD) of hiPSC-CMs have been corrected by clinically used Fridericia's and/or Bazett's formulae, however, the rationale for the use of these formulae has not been well established. In the present study, we developed a correction formula for experiments using hiPSC-CMs. First, we analyzed the effect of beating rate on FPD in the hiPSC-CMs sheets with electrical stimuli and a HCN channel inhibitor zatebradine. Next, we examined the relationship between the electrophysiological properties and the expression levels of ion channel genes in the cell sheets. Zatebradine slowed the beating rate and allowed to analyze FPD changes at various pacing cycle lengths. Rate-dependent change in the repolarization period was smaller in the cell sheets than that reported on the human hearts, which can be partly explained by lower gene expression level of hKCNJ2 and hKCNE1. Thus, non-linear equation for correcting FPD in the cell sheet; FPDc = FPD/RR0.22 with RR given in second was obtained, which may make it feasible to assess net repolarization delay by various chemical compounds with a chronotropic action.

1 January 2017 in The Journal of Toxicological Sciences
Verified
Journal Article
Open access
PDF file
HIHiroko Izumi-Nakaseko
Hiroko Izumi-Nakaseko
YNYuji Nakamura
Yuji Nakamura
TWTakeshi Wada
Takeshi Wada
KAKentaro Ando
Kentaro Ando
YKYasunari Kanda
Yasunari Kanda
ASAtsushi Sugiyama
Atsushi Sugiyama
In order to characterize human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) sheets as a model for detecting drug-induced conduction disturbance, we examined their electrophysiological and electropharmacological properties by using the multi-electrode array system with a programmed electrical stimulation protocol. At pre-drug control, the conduction speed, effective refractory period and field potential duration were 0.14 ± 0.01 m/sec, 453 ± 10 msec and 361 ± 9 msec, respectively at a cycle length of 1,000 msec (n = 18). Shortening the pacing cycle length from 1,000 to 600 msec decreased the conduction speed and field potential duration, but prolonged the effective refractory period. Disopyramide, lidocaine and flecainide decreased the conduction speed but prolonged the effective refractory period and field potential duration, whereas the reverse was true for verapamil. Thus, conduction properties of the cell sheet may largely depend on the extent of Na+ channel availability as is the case in the human ventricle. Importantly, there was no relationship between the conduction delay and 1st spike amplitude reduction after the treatment of Na+ channel blockers. These findings may provide crucial guide on future application of this new technology for early phase safety pharmacological screening of new chemical entities.

20 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KAKentaro Ando
Kentaro Ando
TWTakeshi Wada
Takeshi Wada
XCXin Cao
Xin Cao
Cancer chemotherapies have improved prognosis in cancer patients, resulting in a large and rapidly increasing number of cancer survivors. “Onco-cardiology” or “cardio-oncology” is a new discipline for addressing the unanticipated cardiac side effects of newly developed cancer drugs. Lapatinib, a tyrosine kinase inhibitor suppressing the epidermal growth factor receptor and ErbB2, has been used in advanced or metastatic breast cancer treatment. Reportedly, lapatinib has induced cardiovascular adverse events including QT-interval prolongation and heart failure. However, they have not been predicted by preclinical studies. Hence, a new method to assess the tyrosine kinase inhibitor-induced adverse effects needs to be established. Here, we intravenously administered lapatinib to halothane-anaesthetised dogs, evaluating cardiohemodynamic, electrophysiological, and echocardiographic profiles for pharmacological safety assessments. We intravenously administered lapatinib to chronic atrioventricular block beagle dogs to assess its proarrhythmic potential. The therapeutic concentration of lapatinib significantly increased total peripheral vascular resistance, QT, QTc, monophasic action potential (MAP)90(sinus), MAP90(CL400), effective refractory period, and plasma concentration of cardiac troponin I (cTnI), suggesting that lapatinib prolonged the ventricular repolarization without inducing lethal ventricular arrhythmia. Careful monitoring of plasma cTnI concentration and an electrocardiogram could be supportive biomarkers, predicting the onset of lapatinib-induced cardiovascular adverse events.